NEXTBio Capital Management LP Takes Position in Oric Pharmaceuticals, Inc. $ORIC

Posted by Brian Himes on Jun 14th, 2026

NEXTBio Capital Management LP purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 615,720 shares of the company’s stock, valued at approximately $5,037,000. Oric Pharmaceuticals accounts for 3.0% of NEXTBio Capital Management LP’s holdings, making the stock its 14th largest position.

Several other hedge funds and other institutional investors have also modified their holdings of ORIC. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Oric Pharmaceuticals by 100.0% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after buying an additional 2,000 shares during the period. Assetmark Inc. acquired a new position in shares of Oric Pharmaceuticals in the 3rd quarter valued at about $37,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Oric Pharmaceuticals by 184.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after buying an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Oric Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after buying an additional 977 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Oric Pharmaceuticals in the 3rd quarter valued at about $60,000. 95.05% of the stock is owned by institutional investors and hedge funds.

Oric Pharmaceuticals Trading Up 5.8%

Shares of NASDAQ:ORIC opened at $8.27 on Friday. The company has a 50 day moving average of $9.03 and a 200-day moving average of $10.17. The firm has a market cap of $856.11 million, a P/E ratio of -5.74 and a beta of 1.04. Oric Pharmaceuticals, Inc. has a twelve month low of $7.23 and a twelve month high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). Equities research analysts forecast that Oric Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Wedbush decreased their price target on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, April 1st. The Goldman Sachs Group raised shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a report on Friday, May 15th. Citigroup decreased their price target on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.92.

Read Our Latest Stock Report on ORIC

Oric Pharmaceuticals Company Profile

(Free Report)

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.